ARTICLE | Clinical News
CRx-401 meets diabetes endpoint
May 28, 2009 1:21 AM UTC
CombinatoRx Inc. (NASDAQ:CRXX) said CRx-401 plus metformin met the primary endpoint of significantly reducing fasting plasma glucose at day 90 compared to bezafibrate plus metformin in the Phase II CR...